Nations Financial Group Inc. IA ADV acquired a new position in AstraZeneca PLC (OTCMKTS:AZNCF – Free Report) in the 1st quarter, Holdings Channel.com reports. The institutional investor acquired 3,626 shares of the company’s stock, valued at approximately $715,000.
A number of other hedge funds have also bought and sold shares of AZNCF. Saranac Partners Ltd purchased a new stake in shares of AstraZeneca during the 3rd quarter valued at about $876,000. Mascoma Wealth Management LLC bought a new stake in shares of AstraZeneca in the fourth quarter worth approximately $46,000. Valley Wealth Managers Inc. purchased a new position in shares of AstraZeneca during the fourth quarter valued at approximately $144,000. Hendley & Co. Inc. purchased a new position in shares of AstraZeneca during the fourth quarter valued at approximately $11,373,000. Finally, L & S Advisors Inc bought a new position in AstraZeneca during the fourth quarter valued at approximately $14,863,000. Hedge funds and other institutional investors own 40.87% of the company’s stock.
AstraZeneca Stock Performance
Shares of AZNCF stock opened at $187.10 on Wednesday. AstraZeneca PLC has a 12-month low of $122.26 and a 12-month high of $195.00. The firm’s 50 day moving average is $187.10 and its 200 day moving average is $186.15.
AstraZeneca Profile
AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.
The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.
Featured Stories
- Five stocks we like better than AstraZeneca
- Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning
- Apple’s Intel Deal Arrives at the Right Time for Its Stock
- Liquid Gold: The AI Cooling Retrofit Trade
- 3 Dividend Stocks Under $30 to Anchor Your Portfolio
Want to see what other hedge funds are holding AZNCF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (OTCMKTS:AZNCF – Free Report).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
